Thyroid Uptake Measurement: RAIU & Probe QC

The radioactive iodine uptake (RAIU) test quantifies the fraction of administered radioiodine that the thyroid traps and retains at a fixed time — and that single percentage can decide a diagnosis and a therapy dose. Because it is a quantitative measurement rather than a picture, the result is only as trustworthy as the uptake probe calibration, the decay-corrected standard, the counting geometry, and the corrections applied for background and tissue attenuation.¹²

A defensible RAIU program treats the uptake probe as a quantitative instrument with its own quality-control schedule, uses a standard that mimics neck geometry, and accounts for the radionuclide, timing, and patient iodine status before the percent uptake is reported.¹³ This guide explains the physics, the calculation, the QC, normal ranges, and the pitfalls.

Introduction

Thyroid uptake is one of the oldest quantitative measurements in nuclear medicine, and it remains clinically decisive: it separates the high-uptake causes of hyperthyroidism from the low-uptake causes, and it feeds directly into radioiodine therapy planning. Graves' disease, toxic multinodular goiter, and toxic adenoma drive uptake up; subacute, painless, and postpartum thyroiditis, factitious thyrotoxicosis, and recent iodine exposure drive it down. A correct percent uptake points toward the right management; a wrong one can send a patient toward an inappropriate therapy.¹⁸

Unlike most nuclear medicine, RAIU does not depend on a gamma camera. It uses a dedicated thyroid uptake probe — a single sodium iodide scintillation detector with a collimator — counting the neck and comparing it to a reference standard. That simplicity is also the risk: with no image to inspect, every error in calibration, geometry, decay correction, or background propagates straight into the reported number.¹²

This article walks through the measurement chain, the uptake-probe QC program, the percent-uptake calculation with worked decay correction, normal ranges, clinical impact, practical tips, and the regulatory context. DRPS supports nuclear medicine and thyroid programs through its PET/CT and nuclear medicine physics services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Topic Explanation

What is the RAIU test?

The RAIU test measures the percentage of an administered radioiodine dose that the thyroid has trapped at a defined time after administration. The patient ingests a small capsule or liquid of radioiodine; after a trapping-and-organification interval, a collimated probe counts the photons emerging from the neck. The same probe counts a reference standard of known activity in a neck phantom, and the ratio gives the percent uptake.¹

Key terms used throughout this guide:

Uptake probe — a collimated sodium iodide (NaI(Tl)) scintillation detector with a single-channel or multichannel analyzer, used for counting rather than imaging.
Reference standard — a capsule or source of known activity, ideally from the same lot as the patient dose, counted in a neck phantom to mimic geometry.
Neck phantom — a tissue-equivalent block with a cavity at thyroid depth that reproduces source-to-detector geometry and attenuation.
Background / thigh count — a count over a non-thyroidal site (commonly the thigh) used to subtract extrathyroidal and ambient activity.
Photopeak window — the energy window centered on the radionuclide's principal photon, set during energy calibration.

Which radionuclide, and why it matters

The choice of radionuclide changes the photon energy, the radiation dose, and what is actually being measured. The table below compares the common agents.¹²

Agent	Principal photon	Physical half-life	What it measures	Typical role
Iodine-123 (NaI)	159 keV	~13.2 h	Trapping and organification	Preferred diagnostic uptake and scintigraphy
Iodine-131 (NaI)	364 keV	~8.02 d	Trapping and organification	Uptake for therapy planning; higher patient dose
Technetium-99m pertechnetate	140 keV	~6.0 h	Trapping only (not organified)	Imaging of trapping function; not a true iodine-uptake measurement

Iodine-123 is generally preferred for diagnostic uptake because its 159 keV photon images well and delivers a comparatively low thyroid dose. Iodine-131, with its 364 keV photon and 8.02-day half-life, delivers a substantially higher dose and is more often used when uptake is measured as part of therapy planning. Technetium-99m pertechnetate is trapped but not organified, so it reflects trapping function and is an imaging agent rather than a true iodine-uptake measurement.¹² For background on isotope selection across nuclear medicine, see our overview of common PET and radiopharmaceutical-therapy isotopes.

Key Technical Principles

The percent-uptake calculation

The percent uptake compares net thyroid counts to the counts from a decay-corrected standard measured in identical geometry. In its general form:

% Uptake = \frac{C _{neck} - C _{thigh}}{C _{std}^{corr}} \times 100

where $C_{neck}$ is the gross neck count, $C_{thigh}$ is the background (thigh) count subtracting extrathyroidal and ambient activity, and $C_{std}^{corr}$ is the standard count decay-corrected to the time of the neck measurement and corrected for its own room background. All counts must use the same counting time, source-to-detector distance, collimation, and energy window; otherwise the ratio is not valid.¹

Decay correction of the standard

Because the standard is usually counted at administration time but the neck is counted hours later, the standard count must be decay-corrected forward to the neck-measurement time. Radioactive decay follows:

A (t) = A_{0} e^{- λ t}, λ = \frac{ln 2}{T _{1/2}}

so the decay-corrected standard count is:

C_{std}^{corr} = C_{std}^{0} e^{- λ t}

where $t$ is the elapsed time between the standard count and the neck count. For iodine-123 ( $T_{1/2} \approx 13.2$ h), the decay constant is:

λ = \frac{ln 2}{13.2 h} \approx 0.0525 h^{- 1}

Worked example: a 24-hour I-123 uptake

Suppose an I-123 standard counted at administration gives $C_{std}^{0} = 480, 000$ counts (net of room background). At 24 hours, the patient's neck gives $C_{neck} = 96, 500$ counts and the thigh background gives $C_{thigh} = 4, 500$ counts, each for the same counting time. First, decay-correct the standard to 24 hours:

C_{std}^{corr} = 480, 000 \times e^{- 0.0525 \times 24} \approx 480, 000 \times 0.284 \approx 136, 300 counts

Then compute the uptake:

% Uptake = \frac{96 , 500 - 4 , 500}{136 , 300} \times 100 \approx 67.5%

A 24-hour uptake near 67% is markedly elevated and, with a suppressed TSH and a diffusely enlarged gland, is consistent with Graves' disease. Note how sensitive the result is to the decay correction: omitting it would divide by 480,000 instead of 136,300 and report roughly 19% — a value that could be misread as low-normal. Decay correction is not a formality; it is the difference between a high-uptake and a low-uptake interpretation.¹

Why the standard and geometry must match the patient

The standard count stands in for "100% of the administered activity counted in neck geometry." If the standard is a different lot, a different volume, or counted at a different distance or in air instead of the neck phantom, the denominator is wrong and so is the uptake. Best practice is to use a standard from the same lot as the patient dose, counted in a neck phantom at the same probe-to-source distance used for the patient, with the same energy window and counting time.¹² Attenuation by neck tissue also matters: counting the standard in a tissue-equivalent phantom approximates the attenuation the patient's photons experience, which is why an "in-air" standard systematically overstates uptake.

Clinical Impact

The percent uptake is diagnostically decisive precisely because high-uptake and low-uptake thyrotoxicosis are managed very differently. A high uptake points toward Graves' disease or nodular autonomy, which respond to radioiodine therapy; a low uptake points toward thyroiditis, exogenous thyroid hormone, or iodine load, which do not — and would be harmed by an unnecessary radioiodine treatment.¹⁸

Reported reference ranges vary with dietary iodine, but published data give a useful frame. According to PubMed, a study of euthyroid and hyperthyroid patients reported a mean 24-hour radioiodine uptake of about 15% ± 7% in the euthyroid group and about 40% ± 14% in the Graves' disease group, with subacute thyroiditis near 3% ± 4% — illustrating how the test separates these entities (DOI).⁵ A commonly used normal 24-hour range is roughly 10–30%, but each laboratory should understand the range that applies to its population and method.¹⁵

Reproducibility is clinically relevant because uptake feeds therapy dosing. According to PubMed, a study of repeated I-131 uptake measurements under stable geometry found high reproducibility, with least-significant-change values on the order of about 1% uptake at 24 hours when measurements are made carefully (DOI) — but that reproducibility depends on disciplined geometry and QC, which is exactly what degrades when the probe program is neglected.⁶ Therapy planning also depends on retention kinetics; the effective half-life of I-131 in the gland can shift with preparation, for example after recombinant human TSH stimulation, which according to PubMed significantly shortened the effective half-life compared with thyroid-hormone withdrawal (DOI).⁷

Practical Optimization Tips

A defensible RAIU program runs the uptake probe as a calibrated quantitative instrument and controls the measurement geometry tightly.

1. Run a daily probe QC routine

Before patient measurements, perform an energy-peak (photopeak) calibration for the radionuclide in use, a constancy check with a long-lived reference source (commonly Cs-137 or Co-57), and a background count. Confirm the measured constancy source counts are within the established control limits (commonly ±10% of the reference, or tighter per local policy).

2. Establish probe efficiency, linearity, and energy resolution periodically

Beyond daily checks, the physicist should periodically verify counting efficiency, linearity across the count-rate range (including chance-coincidence/dead-time behavior at high rates), and energy resolution of the NaI(Tl) detector. Degraded resolution or dead-time losses bias quantitative counts.

3. Match geometry rigorously

Use a neck phantom for the standard, fix the probe-to-source distance (commonly ~25–30 cm per protocol), and use the same counting time and energy window for neck, thigh, and standard. Document the geometry so it is reproducible between visits and between technologists.¹

4. Always decay-correct the standard and subtract background

Decay-correct the standard to the neck-measurement time and subtract both the thigh (patient background) and room background. As the worked example shows, omitting decay correction can turn a high uptake into an apparently low one.¹

5. Screen for recent iodine exposure and medications

Document iodinated contrast, amiodarone, thyroid hormone, and iodine-rich diet before the study. These expand the stable iodine pool and suppress measured uptake for weeks to months, and they must be considered before interpreting a low result.¹⁸

Common RAIU pitfalls to avoid

Skipping or mis-timing decay correction — the single most consequential arithmetic error in the test.¹
Counting the standard in air — overstates uptake because it omits neck-tissue attenuation.
Changing geometry between standard and patient — different distance, window, or counting time invalidates the ratio.
Ignoring recent iodine load — a suppressed uptake from contrast or amiodarone can mimic thyroiditis.
Neglecting probe QC — a drifted photopeak or dead-time loss silently biases every result.
Applying another lab's normal range — reference values depend on local dietary iodine and methodology.⁵

Regulatory Considerations

Radioiodine is byproduct material, so the RAIU program operates under NRC or Agreement State medical-use rules, with the uptake probe governed by the facility's radiation-safety and quality-management program. Because I-123 and I-131 are radioactive material, possession and medical use fall under 10 CFR Part 35 (or the equivalent Agreement State program), with dose limits under 10 CFR Part 20.

10 CFR Part 35 — Medical Use of Byproduct Material. Governs authorized use of radioiodine, instrument and dose-calibrator requirements, and the authorized user and RSO responsibilities relevant to diagnostic and therapeutic radioiodine. When uptake measurements support I-131 therapy, written-directive and patient-release requirements also apply.³
10 CFR Part 20 — Standards for Protection Against Radiation. Sets the occupational and public dose limits underlying the safety program.⁴
NRC NUREG-1556, Volume 9. Program-specific licensing guidance for medical use, including expectations for instrumentation and quality control.⁹
Professional guidance. The EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy defines the methodology, and the American Thyroid Association hyperthyroidism guidelines frame the clinical use of uptake in diagnosis and therapy selection.¹⁸

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must verify which authority issues its license and which requirements apply. For the therapy side of radioiodine, see our guide to patient release after radiopharmaceutical therapy, and for the instrument that calibrates administered activity, see dose calibrator quality control.

Frequently Asked Questions (FAQs)

What is the radioactive iodine uptake (RAIU) test?

The radioactive iodine uptake test measures the fraction of an administered amount of radioiodine that the thyroid gland traps and retains at a fixed time, usually expressed as a percent at 4–6 hours and 24 hours. It is used to evaluate thyroid function, distinguish causes of hyperthyroidism, and help plan radioiodine therapy.

Which radionuclide is used for thyroid uptake measurement?

Iodine-123 is preferred for diagnostic uptake measurement because of its favorable 159 keV photon and low radiation dose. Iodine-131 can be used, especially when uptake is measured as part of therapy planning, while technetium-99m pertechnetate evaluates trapping for imaging but is not iodinated and does not measure organification.

How is percent thyroid uptake calculated?

Percent uptake equals the net counts over the patient's neck, corrected for background, divided by the counts from a decay-corrected reference standard measured in the same geometry, multiplied by 100. Both measurements must use the same counting time, distance, and detector settings, and the standard must be decay-corrected to the time of the neck measurement.

Why does the uptake probe need quality control?

The uptake probe is a quantitative instrument, so a wrong calibration produces a wrong percent uptake and potentially a wrong therapy dose. Daily energy-peak and constancy checks, plus periodic efficiency, linearity, and background checks, confirm the probe is correctly identifying the photopeak and counting reproducibly.

What are normal thyroid uptake values?

Normal 24-hour radioiodine uptake in iodine-sufficient populations is commonly cited in the range of roughly 10–30%, with reported euthyroid means near 15%. Reference ranges depend on dietary iodine intake and local methodology, so each laboratory should understand the values that apply to its population and protocol.

Why does recent iodine exposure affect the uptake test?

Iodinated contrast media, amiodarone, and iodine-rich diets expand the body's stable iodine pool and dilute the radioiodine tracer, suppressing measured uptake for weeks to months. Recent iodine exposure can make a hyperthyroid gland appear to have low uptake and must be accounted for before interpreting the result.

Who should calibrate and oversee the uptake probe?

A qualified or board-certified medical physicist establishes the calibration, efficiency, and quality-control program for the uptake probe, while technologists perform the daily checks. The medical physicist's involvement supports accurate quantification, regulatory compliance, and defensible therapy-planning measurements.

Key Takeaways

RAIU is a quantitative count ratio, not an image, so calibration, geometry, decay correction, and background dominate accuracy.¹
Decay-correct the standard to the neck-measurement time — omitting it can turn a high uptake into an apparently low one, as the worked example shows.¹
Iodine-123 is the preferred diagnostic agent (159 keV, low dose); I-131 is reserved more for therapy-planning uptake; Tc-99m pertechnetate measures trapping only.¹²
The uptake probe needs its own QC: daily photopeak and constancy checks, periodic efficiency, linearity, and energy-resolution verification.
Reference ranges depend on dietary iodine; published euthyroid 24-hour means near 15% and Graves' means near 40% illustrate how the test separates causes of thyrotoxicosis.⁵
Screen for recent iodine exposure: contrast, amiodarone, and iodine-rich diets suppress uptake for weeks to months and can mimic thyroiditis.¹⁸

Conclusion

Thyroid uptake measurement is deceptively simple — a probe, a standard, and a ratio — but that simplicity concentrates the risk in a handful of steps. A correctly calibrated uptake probe, a same-lot standard counted in neck geometry, rigorous decay correction and background subtraction, and a screen for recent iodine exposure are what turn a count ratio into a defensible clinical number. Because that number can decide between radioiodine therapy and watchful management, and because it feeds directly into therapy dosing, the quality-control discipline behind it is not optional.¹⁶⁸

Facilities that treat the uptake probe as a quantitative instrument with a documented QC program — rather than a count box — will produce uptake values their physicians and patients can rely on, and stay defensible at inspection.

How DRPS Can Help

Diagnostic Radiation Physics Services supports nuclear medicine and thyroid programs with uptake-probe calibration and quality-control program design, efficiency and linearity verification, geometry and standard protocols, and PET/CT and nuclear medicine physics support by board-certified medical physicists. We also assist with radioactive material license support and radiation safety officer services for facilities running diagnostic and therapeutic radioiodine programs.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware. A reliable uptake program is built on calibrated instruments and disciplined geometry — that is what makes the percent uptake trustworthy.

Related Resources

References

Giovanella L, Avram AM, Iakovou I, et al. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging. 2019;46(12):2514-2525. doi:10.1007/s00259-019-04472-8. doi.org
U.S. National Institute of Standards and Technology. Radionuclide half-life measurements and decay data (iodine-123, iodine-131, technetium-99m). nist.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
Al-Muqbel KM, Tashtoush RM. Patterns of thyroid radioiodine uptake: Jordanian experience. Journal of Nuclear Medicine Technology. 2010;38(1):32-36. doi:10.2967/jnmt.109.069146. doi.org
Şahmaran T, Gültekin SS. Least significant changes and reproducibility of 131I uptake test. Health Physics. 2021;120(3):316-320. doi:10.1097/HP.0000000000001325. doi.org
Menzel C, Kranert WT, Döbert N, et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I. Journal of Nuclear Medicine. 2003;44(7):1065-1068. PubMed
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229. doi.org
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Consolidated Guidance About Materials Licenses — Program-Specific Guidance About Medical Use Licenses. nrc.gov